In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer

Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model that recapitulates clinical invasive prostate cancer in a genome-wide CRISPR...

Descripción completa

Detalles Bibliográficos
Autores principales: Rushworth, Linda K, Harle, Victoria, Repiscak, Peter, Clark, William, Shaw, Robin, Hall, Holly, Bushell, Martin, Leung, Hing Y, Patel, Rachana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Life Science Alliance LLC 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556750/
https://www.ncbi.nlm.nih.gov/pubmed/33033111
http://dx.doi.org/10.26508/lsa.202000770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556750/
https://www.ncbi.nlm.nih.gov/pubmed/33033111
http://dx.doi.org/10.26508/lsa.202000770

Ejemplares similares